Oncology and Hematology

91-105 of 290

• 

  RestartResume

  Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC

  MinuteCE®

  Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC

  • 

    

    Stephen Liu, MD

    Peer

  • 

    

    Joshua K. Sabari, MD

    Peer

  • 

    

    Susan Scott, MD

    Peer

  1.25 program credits

• 

  RestartResume

  HER2-Driven Strategies in Metastatic NSCLC

  MinuteCE®

  HER2-Driven Strategies in Metastatic NSCLC

  • 

    

    Stephen Liu, MD

    Peer

  • 

    

    Joshua K. Sabari, MD

    Peer

  • 

    

    Susan Scott, MD

    Peer

  1.25 program credits

• 

  RestartResume

  MET and Other Emerging Targets in Metastatic NSCLC

  MinuteCE®

  MET and Other Emerging Targets in Metastatic NSCLC

  • 

    

    Stephen Liu, MD

    Peer

  • 

    

    Joshua K. Sabari, MD

    Peer

  • 

    

    Susan Scott, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC

  MinuteCE®

  Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC

  • 

    

    Stephen Liu, MD

    Peer

  • 

    

    Joshua K. Sabari, MD

    Peer

  • 

    

    Susan Scott, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma

  MinuteCE®

  Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma

  • 

    

    John M. Kirkwood, MD

    Peer

  • 

    

    Sapna Patel, MD

    Peer

  1.00 program credits

• 

  RestartResume

  Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma

  MinuteCE®

  Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma

  • 

    

    John M. Kirkwood, MD

    Peer

  • 

    

    Sapna Patel, MD

    Peer

  1.00 program credits
• advertisement

• 

  RestartResume

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma

  MinuteCE®

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma

  • 

    

    Paolo A. Ascierto, MD

    Peer

  1.00 program credits

• 

  RestartResume

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma

  MinuteCE®

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma

  • 

    

    Paolo A. Ascierto, MD

    Peer

  • 

    

    Hussein Tawbi, MD, PhD

    Peer

  1.00 program credits

• 

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma

  MinuteCE®

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma

  • 

    

    Paolo A. Ascierto, MD

    Peer

  • 

    

    Hussein Tawbi, MD, PhD

    Peer

  1.00 program credits

• 

  RestartResume

  Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma

  MinuteCE®

  Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma

  • 

    

    Paolo A. Ascierto, MD

    Peer

  • 

    

    Hussein Tawbi, MD, PhD

    Peer

  1.00 program credits

• 

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma

  MinuteCE®

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma

  • 

    

    Hussein Tawbi, MD, PhD

    Peer

  • 

    

    Sapna Patel, MD

    Peer

  1.00 program credits

• 

  RestartResume

  Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma

  MinuteCE®

  Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma

  • 

    

    Hussein Tawbi, MD, PhD

    Peer

  • 

    

    Sapna Patel, MD

    Peer

  1.00 program credits
• advertisement

• 

  RestartResume

  Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma

  MinuteCE®

  Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma

  • 

    

    Sapna Patel, MD

    Peer

  • 

    

    John M. Kirkwood, MD

    Peer

  1.00 program credits

• 

  RestartResume

  Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management

  MinuteCE®

  Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management

  • 

    

    Hussein Tawbi, MD, PhD

    Peer

  • 

    

    Paolo A. Ascierto, MD

    Peer

  1.00 program credits

• 

  RestartResume

  ADCs Across the Spectrum of HER2 Expression in Metastatic Breast Cancer

  CME/CE

  ADCs Across the Spectrum of HER2 Expression in Metastatic Breast Cancer

  • 

    

    Reshma L. Mahtani, DO

    Peer

  0.25 credits

• Prev
• 1
• 2
• …
• 5
• 6
• 7
• 8
• 9
• …
• 19
• 20
• Next